Document Detail


Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
MedLine Citation:
PMID:  17556354     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The efficacy and safety of lopinavir/ritonavir monotherapy has been explored with promising results in well-controlled, randomized clinical trials. However, less information about its clinical usefulness in routine clinical practice is currently available. The objective of this study was to assess the effectiveness and safety of monotherapy with lopinavir/ritonavir as a treatment simplification strategy in HIV-infected patients with viral suppression outside a clinical trial setting. METHODS: Fifty-one subjects who were switched to lopinavir/ritonavir monotherapy and whose HIV-1 RNA was <50 copies/mL were included in this retrospective study. Data were obtained from a prospectively compiled database. The primary endpoint was the percentage of subjects who maintained viral suppression after 48 weeks of follow-up. Secondary endpoints included the incidence of adverse events and changes in CD4+ T cell count and in lipid profile. RESULTS: Two patients lost viral suppression, seven patients interrupted lopinavir/ritonavir monotherapy because of adverse events and four patients were lost before completing 48 weeks of follow-up. Thus, 38/40 (95.0%) patients maintained viral suppression when only subjects whose outcomes were available up to week 48 were considered and 38/51 (74.5%) patients maintained viral suppression when subjects who discontinued therapy or who were lost to follow-up were considered as treatment failures. The mean CD4+ T cell count significantly increased, from 541 (280) cells/mm3 at baseline to 609 (212) cells/mm3 at week 48 of follow-up (P=0.034). This increase was similar to that observed in the 48 weeks prior to lopinavir/ritonavir monotherapy (P=0.792). Although total cholesterol remained unchanged, there was a significant decrease in triglyceride levels during follow-up (P=0.029). CONCLUSIONS: Monotherapy with lopinavir/ritonavir is safe and effective as a treatment simplification approach in HIV-1-infected patients with sustained viral suppression in routine clinical practice, particularly in those patients already receiving a lopinavir/ritonavir-based antiretroviral regimen.
Authors:
José Moltó; José Ramón Santos; Eugenia Negredo; Cristina Miranda; Sebastià Videla; Bonaventura Clotet
Related Documents :
9734884 - Long-lasting recovery in cd4 t-cell function and viral-load reduction after highly acti...
8730504 - Gisc protocol experience in the treatment of essential mixed cryoglobulinaemia.
17684304 - Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pedi...
11864204 - Low doses of zidovudine plus didanosine are less effective than higher doses of didanos...
475274 - Axillary hyperhidrosis: surgical cure with aesthetic scars.
23703034 - Outcome of mechanical thrombectomy with solitaire stent as first-line intra-arterial tr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-06-07
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  60     ISSN:  0305-7453     ISO Abbreviation:  J. Antimicrob. Chemother.     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-07-16     Completed Date:  2007-11-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  England    
Other Details:
Languages:  eng     Pagination:  436-9     Citation Subset:  IM    
Affiliation:
Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, and Universidad Autónoma de Barcelona, Spain. jmolto@flsida.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-HIV Agents / adverse effects,  therapeutic use*
Antiretroviral Therapy, Highly Active*
CD4 Lymphocyte Count
Cholesterol / blood
Databases, Factual
Endpoint Determination
Female
Genotype
HIV Infections / drug therapy*,  virology
Humans
Lipids / blood
Male
Pyrimidinones / adverse effects,  therapeutic use*
RNA, Viral / genetics,  isolation & purification
Retrospective Studies
Ritonavir / adverse effects,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Lipids; 0/Pyrimidinones; 0/RNA, Viral; 0/Ritonavir; 192725-17-0/lopinavir; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China...
Next Document:  Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: ...